Loss of stromal caveolin-1 expression in colorectal cancer predicts poor survival

Table 1 Association of stromal caveolin-1 expression with clinicopathologic parameters n (%)

Variable	Cav-1			P-value
	0	1	2
Age (yr)				0.0951
≤ 50	22 (33.8)	19 (29.2)	24 (36.9)
> 50	27 (23.9)	31 (27.4)	55 (48.7)
Gender				0.4041
Male	26 (25.2)	29 (28.2)	48 (46.6)
Female	23 (30.7)	21 (28.0)	31 (41.3)
Tumor size (cm)				0.6881
< 5	28 (27.7)	30 (29.7)	43 (42.6)
≥ 5	21 (27.3)	20 (26.0)	36 (46.8)
Tumor location				0.3781
Colon	32 (30.8)	28 (26.9)	44 (42.3)
Rectum	17 (23.3)	22 (30.1)	34 (46.6)
Histological type				0.0222a
Well	1 (12.5)	4 (50.0)	3 (37.5)
Moderate	31 (23.8)	35 (26.9)	64 (49.2)
Poor	17 (42.5)	11 (27.5)	12 (30.0)
Pathologic T stage				0.1182
T1	1 (50.0)	0 (0)	1 (50.0)
T2	0 (0)	5 (35.7)	9 (64.3)
T3	45 (29.2)	44 (28.6)	65 (42.2)
T4	3 (37.5)	1 (12.5)	4 (50.0)
Pathologic N stage				0.0352a
N0	10 (16.4)	20 (32.8)	31 (50.8)
N1	23 (29.1)	23 (29.1)	33 (41.8)
N2	16 (42.1)	7 (18.4)	15 (39.5)
Pathologic TNM stage				0.0472a
I	0 (0)	4 (50.0)	4 (50.0)
II	10 (18.9)	16 (30.2)	27 (50.9)
III	39 (33.3)	30 (25.6)	48 (41.0)
Tumor cell Cav-1				0.6971
Negative	26.7 (61.8)	29.1 (63.8)	76 (44.2)
Positive	3 (50.0)	0 (0)	3 (50.0)
Recurrence				< 0.0011a
No		28 (24.1)	68 (58.6)
Yes		21 (36.2)	10 (17.2)

¹Mann-Whitney test;

²Spearman’s test;

^aP < 0.05, stromal CAV-1 vs clinical variables. CAV-1: Caveolin-1; TNM: Tumor-node-metastasis.